Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Stomach Neoplasms 1Rectal Neoplasms 1Pancreatic Adenocarcinoma Metastatic 1Osteosarcoma 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Digestive System Diseases 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Carcinoma 1Advanced Solid Tumor 1Advanced Pancreatic Cancer 1

Interventions

Bevacizumab 76Fluorouracil 56Cetuximab 47Leucovorin 44Oxaliplatin 43pembrolizumab 35Irinotecan 34Folfox protocol 24Capecitabine 24HMPL-013 22Specimen Handling 18trifluridine tipiracil drug combination 16Nivolumab 15Blood Specimen Collection 15Panitumumab 14regorafenib 13Magnetic Resonance Spectroscopy 13Trifluridine 12Standard of Care 12Gemcitabine 12Biopsy 12Cisplatin 11sintilimab 10Interviews as Topic 10IFL protocol 10Drug Therapy 10Carboplatin 9tislelizumab 8Trastuzumab 8Cyclophosphamide 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Colorectal Neoplasms × penpulimab × Clear all
NCT05229003 2024-07-03

Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC

Fudan University

Phase 2 Recruiting
44 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡